Biochemical Pharmacology volume 80, issue 11, P1727-1735 2010 DOI: 10.1016/j.bcp.2010.08.010 View full text
|
|
Share
Barry D. Kerr, Peter R. Flatt, Victor A. Gault

Abstract: Oxyntomodulin (Oxm) is a hormone which has been shown to exhibit a range of potentially beneficial actions for alleviation of obesity-diabetes. However, exploitation of Oxm-based therapies has been severely restricted due to degradation by the enzyme dipeptidylpeptidase-IV (DPP-IV). Thus, the aim of this study was to assess the glucose-lowering, insulin-releasing and anorexigenic actions of chemically modified, enzyme-resistant analogues of Oxm. Oxm, (d-Ser(2))Oxm and (d-Ser(2))Oxm[mPEG-PAL], were incubated wi…

expand abstract